Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 10/20 | 0.60 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | PTGES | O14684 | 1/20 | 0.45 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.44 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14083363 | 0.89 | TRPV1 (0.61) | TRPV1RPS6KA3GAADYRK1APTGS1 | |
| SCHEMBL14083222 | 0.87 | TRPV1 (0.55) | TRPV1RPS6KA3GAADYRK1APTGES | |
| SCHEMBL14083595 | 0.87 | TRPV1 (0.79) | TRPV1 | |
| SCHEMBL14083617 | 0.86 | TRPV1 (0.57) | TRPV1GAASMN1; SMN2 | |
| SCHEMBL14083615 | 0.86 | RAB9A (0.50) | TRPV1GAASMN1; SMN2TDP1 | |
| SCHEMBL4591053 | 0.85 | TRPV1 (0.78) | TRPV1RPS6KA3PTGS1 | |
| SCHEMBL14083959 | 0.84 | TRPV1 (0.63) | TRPV1RPS6KA3GAADYRK1APTGS1 | |
| SCHEMBL14083172 | 0.83 | TRPV1 (0.50) | TRPV1RPS6KA3GAADYRK1APTGES | |
| SCHEMBL14083336 | 0.82 | TRPV1 (0.49) | TRPV1RPS6KA3GAADYRK1A | |
| SCHEMBL14083613 | 0.81 | TRPV1 (0.48) | TRPV1SMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | KELLY MICHAEL G | 2008-08-21 | — | — | US | disclosed |
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | KELLY MICHAEL G | 2008-08-21 | — | — | US | disclosed |
| US-7338950-B2 | Amide compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-03-04 | — | — | US | disclosed |
| US-7338950-B2 | Amide compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | TRPV1, TRPA1, TRPV2 | TRPV1 1/4885RPS6KA3 1757/4885GAA 3059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.